AR and B-cell chronic lymphocytic leukemia: In conclusion, we report here for the first time AR in patient-derived cancer cells and show that specific targeting of key actin regulators in combination with anti-HLA-G blocking antibody, increases conjugate formation and target cell susceptibility to NK cell-mediated cytotoxicity opening up the possibility of combinational targeting for CLL patients.